Date: 2013-10-15
Type of information: Collaboration agreement
Compound: OmniRat™ and OmniMouse™ transgenic platforms
Company: Symphogen (Denmark) Open Monoclonal Technology (USA)
Therapeutic area:
Type agreement: collaboration
Action mechanism: OmniRat® is the industry’s first fully human monoclonal antibody platform based on rats. It represents a novel and proprietary technology with unrestricted development options for therapeutic antibodies. OMT and Pfizer have demonstrated that OmniRat has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as a wild-type animals make rat antibodies (Journal of Immunology 2013 Feb 15; 190(4):1481-90). OmniMouse® is a transgenic mouse designed to complement OmniRat and further increase epitope coverage in human therapeutic antibody development. Both animals deliver antibodies with great affinity, specificity, expression, solubility and stability, yet with low or no immunogenicity or need for lead optimization. OmniFlic™ is the industry’s first engineered rat with a fixed light chain for development of human bispecific antibodies.
Disease:
Details: * On October 15, 2013, Symphogen, a Danish private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, and Open Monoclonal Technology, an innovator in transgenic animals for development of human therapeutic antibodies, have announced an alliance that provides Symphogen with unlimited access to OMT’s OmniRat® and OmniMouse® platforms. Symphogen will use its proprietary B cell-based antibody identification technology, Symplex™, and access the diverse immune repertoires generated in OMT’s transgenic animals to develop novel human therapeutic candidates.
Financial terms:
Latest news:
